The Proposed UK-EU SPS Agreement and GB BPR: What May Change for Biocide Approvals and Authorisations from 2027

Status on 23 September 2026: proposed, not in force

On 19 May 2025 the UK and the EU agreed to pursue a new SPS agreement. On 22 September 2026 HSE published a dedicated biocides page stating that the government is in 'advanced negotiations' and that, if an agreement is reached, businesses working with biocides 'are likely to see changes to the rules you must follow', including active substance approvals and biocidal product authorisations. Defra's information for businesses states the government's intent that the agreement will take effect in mid-2027, and Defra's published list of legislation expected to be in scope includes Regulation (EU) No 528/2012, the EU Biocidal Products Regulation.

That is the extent of the official position. The text of the agreement has not been published, the biocides provisions have not been agreed in detail, and no UK legislation implementing them has been laid. Everything below about the effects is therefore an inference from the published scope and from how the two regimes currently differ, and it should be read as a developing position. This page carries its date in the heading for that reason, and it will be updated when HSE or Defra publish more.

Why an agrifood agreement reaches biocides at all

SPS rules govern food, feed, animal and plant health. The UK-EU discussions have framed the agreement more broadly, as covering the agrifood rulebook that products must meet to move without checks, and the published scope lists 'regulation of pesticides and biocides' alongside food labelling, organics and marketing standards. The reason is practical: disinfectants used in animal housing, food and feed premises and drinking water for livestock sit inside the food chain, and border checks on animal and food products can only be removed if the underlying rules are recognised as equivalent or aligned.

The model discussed in Parliament and by the government is dynamic alignment: GB rules in scope would follow relevant EU rules as they change, with a role for the EU's institutions in interpreting them and some form of dispute mechanism. Parliamentary debate in February 2026 identified dynamic alignment as the central issue, with pesticides among the areas named. For biocides the government has not yet said whether alignment would be full, partial or subject to exceptions, or how the GB Review Programme and GB Article 95 list would be reconciled with their EU counterparts.

Where GB BPR and EU BPR have diverged since 2021

GB BPR is the retained version of the EU regulation, so the structure is the same: active substances are evaluated and approved per product type, products containing them are then authorised, and suppliers must be on an Article 95 list. Divergence has grown in the detail. Great Britain runs its own Review Programme for existing active substances, with HSE as the evaluating authority and its own timetable; decisions the EU has already taken (approval, non-approval, identity changes) do not apply in GB unless HSE takes them too. GB maintains its own Article 95 list, on which a supplier must appear separately from the EU list. Product authorisations granted by the EU or by an EU member state have no effect in GB, and vice versa, so a product on both markets holds two authorisations or relies on two sets of transitional arrangements. Northern Ireland, under the Windsor Framework, remains within EU BPR.

For chlorine dioxide the practical divergence is in the active substance process. The EU has taken decisions on chlorine dioxide precursor routes for several product types on a different timetable from HSE, and the GB Review Programme has its own evaluation and deadline structure, which HSE's guidance on in-situ generation and transitional supply reflects. Products supplied in GB today under transitional arrangements are doing so because the relevant GB active substance/product type decision has not yet been taken.

What alignment could mean for active substance approvals and product authorisations

If biocides are aligned dynamically, the plausible consequences, none confirmed, are as follows. EU active substance approval decisions, including their conditions and expiry dates, could apply in GB, either automatically or through a fast-track recognition step; the separate GB Review Programme timetable might be superseded, which could either accelerate or bring forward deadlines for products currently on transitional supply. EU product authorisations, or the EU's Union authorisation and mutual recognition routes, might be recognised in GB, reducing duplicate applications; or GB might simply apply the EU rules while keeping HSE as the authorising body. The Article 95 lists could be merged or mutually recognised. Efficacy, labelling and classification requirements could converge where they have drifted apart.

The direction of each change matters for a chlorine dioxide supplier. A product family that already holds or is seeking EU authorisation might find its GB position simplified. A product relying on GB transitional supply might face an earlier or later deadline depending on how the EU decision for its precursor route and product type is transposed. Because chlorine dioxide's regulatory identity is defined by precursor route and product type, not by the molecule alone, alignment would have to be assessed route by route. None of that can be done until the text is published.

What will not change under any published scenario: biocidal products will still need authorisation or lawful transitional status for each product type; suppliers will still need to be on an Article 95 list; efficacy claims will still need to be supported and will still be constrained by the advertising rules; and the separate UK regimes for drinking-water treatment chemicals (DWI Regulation 31 in England and Wales and its equivalents) and for Legionella control (HSE ACOP L8 and HSG274) are not SPS matters and are not in the published scope.

What ChloroKlean is doing and what customers should do

ChloroKlean's products are supplied in Great Britain under GB BPR for their stated product types through the Article 95 supply chain and the transitional arrangements that apply while chlorine dioxide is in the GB Review Programme. That position is unchanged by the negotiations. We are monitoring HSE's SPS biocides page, Defra's business guidance and the eBulletin, and will update this page and the compliance page when the agreement text, the biocides provisions or implementing legislation are published. We will not speculate about product-specific outcomes before then.

Defra's own advice to businesses is to engage with trade bodies and supply chains and to sign up for its updates. In addition, ChloroKlean's suggestion to duty-holders and procurement teams is to keep a current inventory of biocidal products with their product types and authorisation or transitional status, to ask suppliers how they are tracking the agreement, and to treat any claim that a product is 'already SPS-compliant' or that GB BPR requirements have lapsed with scepticism, because there is nothing yet to comply with. Existing GB BPR obligations continue in full until the law changes.

Evidence and uncertainty

Published biofilm studies are valuable for understanding mechanisms, but their conditions may not match a particular installation. Species, surfaces, deposits and operating conditions should be recorded when interpreting evidence.

For safety-critical systems, decisions should be documented through the relevant risk assessment and management plan.

Choosing the next question

A useful next step is to identify what is known, what is inferred and what needs verification. This avoids treating a general reference as a site diagnosis.

Where a product is considered, confirm the intended use, lawful GB BPR route and label directions independently of this educational guide.

Use this sequence to frame investigation and control; it is not a dosing protocol.

Expert Insights

About the Reviewer

Frequently Asked Questions

Common questions about this topic, answered by our technical team.

Related Resources

Continue exploring our knowledge base and product information.